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Abstract 
 
Objective: To use statistical and health economic simulation modelling to estimate the 
cost-effectiveness of a hypothetical follow-up intervention targeted at people who have 
undertaken structured training in flexible intensive insulin therapy, based on their initial 
psychosocial response. 
Research Design and Methods: Data from a psychosocial study of 262 people with 
type 1 diabetes who received structured education in flexible intensive insulin management 
were used.  Multiple linear regression was used to predict HbA1c response following 
structured education (absolute change in HbA1c from baseline to 12 months) from initial 
psychosocial response to structured education (change in psychological questionnaire scores 
from baseline to 3 months).  The Sheffield Type 1 Diabetes Policy Model was used to 
estimate the cost-effectiveness of a follow-up intervention targeted at people not predicted to 
achieve glycaemic targets from the statistical regression equation. 
Results: Initial increases in fear of hypoglycaemia, initial increases in diabetes 
knowledge, higher baseline body mass index and male gender were found to be predictive of 
HbA1c outcome after structured education.  The simulation modelling suggested that a 
follow-up intervention targeted based on the regression equations and costing the same as or 
double a standard five-day structured education program would be cost-effective if it could 
generate a sustained HbA1c improvement of 0.25-0.5%. 
Conclusions: Further research into the design and development of a targeted follow-
up intervention would be beneficial as such an intervention may offer a cost-effective method 
of improving glycaemic outcomes in those patients not achieving glycaemic targets following 
structured education.    
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Introduction 
 
Structured education in flexible intensive insulin therapy has been shown to reduce 
glycosylated haemoglobin (HbA1c) and improve quality of life at six months in people with 
type 1 diabetes in a randomised controlled trial in the United Kingdom (UK) (1).  A 
psychosocial study published in 2013 found that HbA1c and quality of life benefits were also 
observed in routine care (2).  However, HbA1c response to training in flexible intensive 
insulin therapy varies between individuals, with some participants experiencing a significant 
reduction and others, no change over six to 12 months (3).  Additional support following 
structured education may improve glycaemic response in the long term and such a strategy 
could be an effective addition to the clinical care pathway, especially if the follow-up support 
was targeted to those participants most in need.   
 
In England and Wales, the organisation responsible for health technology assessment is the 
National Institute for Health and Clinical Excellence (NICE).  The cost-effectiveness of an 
intervention can be estimated by comparing the outcomes and costs associated with the 
intervention to the next most effective alternative (4).  If these outcomes are estimated as 
quality-adjusted life years (QALYs) as recommended by NICE (5), the incremental cost-
effectiveness ratio, or incremental cost per QALY, can be calculated and compared to 
alternative uses of health care funding.  NICE typically recommends in favour of funding 
interventions with an incremental cost-effectiveness ratio below a threshold of £20,000 per 
QALY (5).  Structured education in flexible intensive insulin therapy has previously been 
shown to be cost-effective in the UK (6). 
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We have hypothesised that it might be possible to predict HbA1c outcomes after people have 
received training in flexible intensive insulin therapy from their early psychosocial response 
to the training.  A follow-up intervention could then be targeted to provide additional support 
to those people that are not predicted to experience a certain level of HbA1c improvement.  
Factors such as expectations of structured education, perceived frequency of hypoglycaemia, 
baseline HbA1c and body mass index (BMI) have previously been shown to predict HbA1c 
levels after structured education in type 1 diabetes (7).  If a targeted follow-up intervention 
could improve the longer-term HbA1c response to structured education it could result in 
lower lifetime incidence of diabetes-related complications and hence cost savings to the 
healthcare system.  In addition to the economic arguments for targeted follow-up support, 
research has shown that some people have expressed dissatisfaction with the support they 
receive following structured training in flexible intensive insulin therapy and have 
emphasised that further individualised support from healthcare professionals may be 
beneficial (8). 
 
The aim of this study was to use statistical and health economic simulation modelling to 
estimate the cost-effectiveness of a hypothetical follow-up intervention targeted at people 
with type 1 diabetes based on their initial psychosocial response to structured education in 
flexible intensive insulin therapy. 
 
Methods 
 
The study consisted of two phases: statistical data analysis to develop predictive equations for 
HbA1c response to training using patient-level data from a study of participants undertaking 
the Dose Adjustment for Normal Eating (DAFNE) structured education program, and health 
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economic simulation modelling to estimate the cost-effectiveness of additional structured 
support from healthcare professions targeted at individuals not predicted to achieve a 
specified level of HbA1c response.. 
 
Data 
 
DAFNE is a five-day structured training program in flexible intensive insulin therapy for 
adults with type 1 diabetes mellitus in the UK, based on a German model (9) with a focus on 
separating basal from mealtime bolus insulin, and carbohydrate counting  to increase dietary 
freedom with bolus insulin adjusted to match flexible food intake.  DAFNE is delivered using 
a structured curriculum to groups of six to eight participants by trained DAFNE educators.  
DAFNE has been shown to improve HbA1c, quality of life and severe hypoglycaemia (1, 3, 
10).  The aforementioned psychosocial study (2) collected data on 262 patients who 
undertook DAFNE training and these data were used to investigate predictors of HbA1c 
response to DAFNE in the current study.  The study was conducted over a 12-month period, 
with a set of psychosocial questionnaires delivered at baseline and at 3-, 6- and 12-month 
follow-up.  The questionnaires included measures of fear of hypoglycaemia (11), illness 
perceptions (12, 13), diabetes knowledge (14), general emotional well-being (15) and life 
satisfaction (16), social support (17, 18), diabetes-specific quality of life (19), diabetes self-
care behaviours (20) and diabetes-specific self-efficacy (21), each producing a summary 
score.  Demographic data and biomedical outcomes including HbA1c were also measured in 
the same participant group at baseline and at 6- and 12-month follow-up. 
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Statistical Analysis 
 
Multiple linear regression was used to estimate predictive models of the change in HbA1c 
from baseline to 12 months in the DAFNE psychosocial study (2).  Linear regression was 
considered an appropriate analysis method because change in HbA1c was normally 
distributed and there were no major departures from linearity or homoscedasticity.  Predictor 
variables included baseline to 3-month change in summary scores from each of the 
psychosocial questionnaires plus biomedical and demographic covariates (age, gender and 
BMI).  Univariate regressions were conducted and those predictor variables that were found 
to be significant at a p<0.10 level were combined in a multivariate model.  Variables were 
then removed if they were no longer significant at the p<0.10 level in the multivariate model 
and did not add substantial predictive power to the model.  Akaike information criterion, 
Bayesian information criterion and adjusted R2 values were compared between models to 
select the most efficient model for change in HbA1c. 
 
Health Economic Simulation Modelling 
 
The Sheffield Type 1 Diabetes Policy Model, a patient-level simulation model of type 1 
diabetes, was used to conduct the economic evaluation (22).  The model simulates individuals 
with type 1 diabetes and uses their characteristics, including HbA1c, to predict the incidence 
of long-term diabetes-related complications and short-term adverse events.  The simulated 
events include microvascular complications (nephropathy, neuropathy, retinopathy and 
macular oedema), macrovascular complications (myocardial infarction, stroke, heart failure 
and angina) and adverse events (severe hypoglycaemia and diabetic ketoacidosis).  The risks 
of developing these events are based on clinical and epidemiological literature (23-29).  
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Figure 1 presents an overview of the structure of the model.  The model uses annual time 
cycles, and during each year probabilities are compared against random numbers to 
determine whether each patient progresses to a more severe health state for each 
complication.  Individuals exit the model if they experience a fatal diabetes-related 
complication, if they die of non-diabetic causes, or if the specified model time horizon is 
reached.  Further details of the structure, data sources and processes of the Sheffield Type 1 
Diabetes Policy Model have been reported elsewhere (22). 
 Figure 1: The Sheffield Type 1 Diabetes Policy Model
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The model was used to simulate the lifetime costs and QALYs for 50,000 individuals under 
two treatment conditions:  an intervention group (“targeted follow-up”) in which people 
predicted from their 3-month change in psychosocial characteristics not to experience at least 
a 0.5% reduction in HbA1c by 12 months were assumed to receive a hypothetical follow-up 
intervention that incurred costs and generated a HbA1c reduction versus a control group in 
which no-one received targeted follow-up after structured training (“current practice”).  All 
costs are reported in 2011-12 £GBP.  “What If?” scenario analyses were run to explore the 
cost-effectiveness of an intervention which achieves an improvement in HbA1c of 0.25%, 
0.5% and 1% at an additional cost the same as (£359 per person (30)) or double (£718 per 
person) the cost of the DAFNE structured education program.  This covers a scenario where 
follow-up would be delivered in a group setting and the potentially more expensive option of 
individual follow-up support.  The cost and HbA1c benefit of targeted follow-up was 
assumed to be the same for all participants that received the follow-up intervention. 
 
The 50,000 simulated individuals were representative of the participants in the DAFNE 
psychosocial study (2).  Costs and QALYs were estimated over a lifetime horizon from an 
NHS perspective and discounted at a rate of 3.5% as recommended by NICE (5). 
 
Results 
 
Statistical Analysis 
 
The regression model suggested that 3-month improvement in fear of hypoglycaemia, 3-
month improvement in diabetes knowledge, higher BMI and male gender were predictive of 
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12-month improvement in HbA1c following training in flexible intensive insulin therapy.  
Table 1 presents the results of the regression model.  Using a liberal alpha level of p < 0.10 
the results suggested that males, people with higher BMI, people with a larger increase in fear 
of hypoglycaemia and people with a larger increase in diabetes knowledge after undertaking 
training in flexible intensive insulin therapy would be more likely to experience a reduction 
in HbA1c over the first 12 months after undertaking structured education.  The regression 
model explained just 6.4% of the variance in 12-month change in HbA1c, indicating very low 
predictive power. 
 
Table 1: Multiple linear regression model of change in HbA1c from baseline to 12 
months on 3-month change predictors 
Predictor variable Coefficient Standard 
error 
P-
value 
Constant 0.657 0.462 0.157 
3-month change in fear of hypoglycaemia (continuous) -0.017 0.010 0.086 
3-month change in diabetes knowledge (continuous) -0.063 0.038 0.097 
Body mass index (continuous) -0.028 0.017 0.105 
Gender (male = 1; female = 0) -0.334 0.157 0.035 
Adjusted R2 = 0.064 
 
The predictive equation from the regression model was: 
 
   =   +  0.657 − 0.017  − 0.063  − 0.028  − 0.334   (Eq. 1) 
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Where Y1 = 12-month HbA1c 
 Y0 = Baseline HbA1c (continuous) 
 x1 = 3-month fear of hypoglycaemia – baseline fear of hypoglycaemia (continuous) 
 x2 = 3-month diabetes knowledge – baseline diabetes knowledge (continuous) 
 x3 = BMI (continuous) 
x4 = Gender (male = 1; female = 0). 
 
Health Economic Simulation Modelling 
 
The modelling suggested that most participants undertaking structured training (85%) would 
require targeted follow-up based on their 12-month HbA1c value predicted from their BMI, 
gender, 3-month change in fear of hypoglycaemia and 3-month change in diabetes knowledge 
using the regression model outlined above.  15% of people were predicted to achieve 
glycaemic targets of a 0.5% improvement following structured education and therefore were 
assumed not to require additional support.  These predictions were based on the criterion that 
people would receive targeted additional support if they were predicted to have less than 
0.5% (5mmol/mol) HbA1c improvement at 12 months. 
 
The results of the simulation modelling are presented in Table 2 and Figure 2.  The 
simulation modelling suggested that targeted support costing the same as a five-day 
structured education program teaching flexible intensive insulin therapy (£359) could 
dominate current practice (i.e. generate more QALYs for lower costs) over a lifetime horizon 
if it generated a 12-month HbA1c reduction of 0.5% or more.  If a targeted follow-up 
intervention costing £359 generated a 12-month HbA1c reduction of just 0.25%, it was 
estimated that it would generate more QALYs for higher costs over a lifetime horizon.  The 
12 
 
incremental cost-effectiveness ratio under these assumptions was £1,605 per QALY which is 
still well below the NICE threshold of £20,000 per QALY and therefore under these 
assumptions a targeted follow-up intervention would still be considered cost-effective. 
 
Table 2: Economic evaluation of a targeted follow-up intervention versus current 
practice 
 Mean 
discounted 
cost 
Mean 
discounted 
QALY 
Incremental 
discounted 
cost 
Incremental 
discounted 
QALY 
ICER 
Current practice 
 
£47,632 10.5841 - - - 
Targeted follow-up cost £359 
and generated -0.25% HbA1c 
reduction 
£47,650 10.5947 £17 0.0106 £1,605 
Targeted follow-up cost £359 
and generated -0.5% HbA1c 
reduction 
£47,582 10.6014 -£51 0.0173 Dominant 
Targeted follow-up cost £359 
and generated -1.0% HbA1c 
reduction 
£47,365 10.6221 -£268 0.0380 Dominant 
Targeted follow-up cost £718 
and generated -0.25% HbA1c 
reduction 
£47,956 10.5947 £323 0.0106 £30,411 
Targeted follow-up cost £718 
and generated -0.5% HbA1c 
reduction 
£47,888 10.6014 £256 0.0173 £14,734 
Targeted follow-up cost £718 
and generated -1.0% HbA1c 
reduction 
£47,671 10.6221 £38 0.0380 £1,004 
 
  
 Figure 2: The cost-effectiveness of targeted follow
effectiveness plane 
 
 
These results were sensitive to the assumed cost of the targeted follow
targeted follow-up intervention was assumed to cost double that of a five
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incremental cost-effectiveness ratio below £20,000 per QALY), based on the assumption that 
it would lead to a 12-month HbA1c reduction of 0.5% or more.    If
intervention costing £718 was assumed to generate a 12
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QALY the targeted follow-up intervention would not be considered cost
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Most of the differences in costs between the targeted follow-up intervention and the current 
practice control were due to reduced incidence and progression of nephropathy and 
retinopathy.  The differences in QALYs between targeted follow-up and current practice 
were largely due to extended life expectancy as well as reduced incidence and progression of 
nephropathy, neuropathy and retinopathy. 
 
Discussion 
 
This economic evaluation used a patient-level simulation model of type 1 diabetes to evaluate 
the potential cost-effectiveness of providing structured follow-up intervention to adults who 
are predicted not to achieve a glycaemic target of a 0.5% HbA1c improvement following 
structured education on flexible intensive insulin therapy.  The results of the analysis 
suggested that increases in fear of hypoglycaemia and diabetes knowledge are predictive of 
HbA1c response to structured education.  The health economic simulation modelling 
indicated that targeted support costing the same or double the cost of a five-day UK 
structured education program could be cost-effective if a 0.25% or 0.5% HbA1c reduction 
could be realised respectively.  These levels are similar to the 0.5% (6 months) and 0.3% (12 
months) reductions observed following initial structured education in routine care (2). 
 
The results of this health economic simulation modelling exercise are dependent on 
assumptions about the effectiveness of the hypothetical targeted follow-up intervention and 
therefore their applicability to clinical practice is limited.  The likelihood that a targeted 
follow-up intervention could generate adequate HbA1c benefit (i.e. a reduction of 0.5% or 
more) is uncertain, and this uncertainty was not captured in the current analysis.  A German 
study found that a teaching and treatment program, for patients with type 1 diabetes that 
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failed to achieve therapeutic goals despite their participation in standard training programs, 
did not generate a statistically significant change in HbA1c at 18 months, although a 
reduction in the incidence of severe hypoglycaemia was observed (31). 
 
People with type 1 diabetes have requested more ongoing support following structured 
training in flexible intensive insulin therapy in the UK; particularly individual level follow-up 
support from healthcare professionals (8).  Coupled with the evidence from the present study 
that additional follow-up support may be cost-effective, this emphasises the need for further 
research into the most effective ways of supporting people with type 1 diabetes following 
structured training. 
 
This study has several limitations that should be considered when interpreting these results. 
First, the hypothetical nature of the assumptions regarding the cost and treatment effect of the 
targeted follow-up intervention means there is no immediate applicability of the findings to 
clinical practice.  Second, the statistical analysis generally had poor predictive power for 
HbA1c response after structured education.  Most people receiving structured education were 
predicted from the regression model not to achieve the HbA1c target of a 0.5% improvement 
and therefore were assumed to require targeted follow-up.  If response to standard structured 
education programs could be predicted more reliably then targeting could be more efficient 
and the cost-effectiveness of the intervention could be improved.  Additional variables that 
have been shown to be predictive of HbA1c response after structured education but were not 
collected in the psychosocial study (2) such as expectations about the course (7) or measures 
of diabetes-specific self-care behaviours taught during structured education could be included 
in future studies aiming to predict HbA1c outcomes.  Third, the model did not fully account 
for uncertainty in model inputs by conducting probabilistic sensitivity analyses.  Finally, the 
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analysis did not account for variability in response to targeted follow-up, assuming instead 
that follow-up generated the same level of HbA1c improvement for all individuals. 
 
The methods employed in this study could be further expanded to inform the design, 
development and pilot evaluation of a targeted follow-up intervention following structured 
education in flexible intensive insulin therapy.  For example, the Sheffield Type 1 Diabetes 
Policy Model could be used to estimate which area of benefit of a follow-up intervention 
(HbA1c, incidence of severe hypoglycaemia or quality of life) it would be most worth 
investing in.   
 
This study has demonstrated the potential cost-effectiveness of a targeted follow-up 
intervention following structured training in flexible intensive insulin therapy for adults with 
type 1 diabetes.  The economic case for funding structured follow-up support could be further 
strengthened if outcomes following structured training could be predicted with greater power.  
Further research into the design and development of a targeted follow-up intervention is 
indicated as such an intervention may improve glycaemic outcomes in those patients not 
achieving glycaemic targets following structured education. 
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